مشخصات مقاله | |
ترجمه عنوان مقاله |
مرور اصولی و فراتحلیلی از بهره وری و ایمنی رازاگیلین و پرامی پکسول در درمان بیماری پارکینسون اولیه |
عنوان انگلیسی مقاله | A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease |
نشریه | هینداوی |
سال انتشار | ۲۰۲۴ |
تعداد صفحات مقاله انگلیسی | ۱۷ صفحه |
هزینه | دانلود مقاله انگلیسی رایگان میباشد. |
نوع نگارش مقاله |
مقاله مروری (Review Article) |
مقاله بیس | این مقاله بیس نمیباشد |
نمایه (index) | Scopus – Master Journals List – JCR – DOAJ – PubMed Central |
نوع مقاله | ISI |
فرمت مقاله انگلیسی | |
ایمپکت فاکتور(IF) |
۳٫۰۴۰ در سال ۲۰۲۲ |
شاخص H_index | ۵۴ در سال ۲۰۲۴ |
شاخص SJR | ۰٫۵۸۴ در سال ۲۰۲۲ |
شناسه ISSN | ۲۰۴۲-۰۰۸۰ |
شاخص Quartile (چارک) | Q3 در سال ۲۰۲۲ |
فرضیه | ندارد |
مدل مفهومی | ندارد |
پرسشنامه | ندارد |
متغیر | ندارد |
رفرنس | دارد |
رشته های مرتبط | پزشکی |
گرایش های مرتبط | مغز و اعصاب |
نوع ارائه مقاله |
ژورنال |
مجله / کنفرانس | بیماری پارکینسون – Parkinson’s Disease |
دانشگاه | University of Eastern Finland, Finland |
شناسه دیجیتال – doi |
https://doi.org/10.1155/2024/8448584 |
لینک سایت مرجع |
https://www.hindawi.com/journals/pd/2024/8448584/ |
کد محصول | e17656 |
وضعیت ترجمه مقاله | ترجمه آماده این مقاله موجود نمیباشد. میتوانید از طریق دکمه پایین سفارش دهید. |
دانلود رایگان مقاله | دانلود رایگان مقاله انگلیسی |
سفارش ترجمه این مقاله | سفارش ترجمه این مقاله |
فهرست مطالب مقاله: |
Abstract Introduction Materials and Methods Results Discussion Data Availability Disclosure Conflicts of Interest Supplementary Materials References |
بخشی از متن مقاله: |
Abstract Background. Rasagiline or pramipexole monotherapy has been suggested for the management of early Parkinson’s disease (PD). The aim of this research was to systematically review the clinical efficacy and safety of rasagiline or pramipexole in early PD (defined as disease duration ≤۵ years and Hoehn and Yahr stage of ≤۳). Methods. Randomized controlled trials (RCTs) of rasagiline or pramipexole for early PD published up to September 2021 were retrieved. Outcomes of interest included changes in the Unified Parkinson’s Disease Rating Scale (UPDRS) Parts II and III and the incidence of adverse events. Standardized mean difference (SMD), odds ratio (OR), and 95% confidence interval (CI) were calculated, and heterogeneity was measured with the I2 test. Results. Nine rasagiline and eleven pramipexole RCTs were included. One post hoc analysis of one rasagiline study was included. Five studies for each drug were included in meta-analyses of the UPDRS scores. The rasagiline meta-analysis focused on patients receiving 1 mg/day. Rasagiline and pramipexole significantly improved UPDRS Part II and III scores when compared to placebo. Significant heterogeneity among the studies was present (I2 > ۷۰%). Neither rasagiline nor pramipexole increased the relative risk for any adverse events, serious adverse events, or adverse events leading to withdrawal when compared with placebo. Conclusion. Applying a Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach to summarize the evidence, we found moderate confidence in the body of evidence for the efficacy of rasagiline or pramipexole in early PD, suggesting further well-designed, multicenter comparative RCTs remain needed.
Introduction Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized clinically by bradykinesia, tremor, rigidity, and postural instability and histologically by neuronal inclusions composed of α-synuclein. Nonmotor symptoms including olfactory dysfunction, rapid eye movement, sleep behavior disorder, mood disorders, and autonomic dysfunction often precede the appearance of motor symptoms by several months or years [1, 2]. These motor and nonmotor symptoms can adversely affect a patient’s quality of life [3]. The incidence of PD is rising and increases with age [4, 5].
Early management of PD could prolong the ability of a patient to stay in working life and improve their overall quality of life [6, 7]. Levodopa is widely considered one of the most effective treatments for PD, but its use is often delayed because of drug-induced dyskinesias and wearing-off and on-off fluctuations [8, 9]. Alternatives to levodopa in early pharmacologic treatment of PD are dopamine agonists and monoamine oxidase B (MAO-B) inhibitors [10, 11]. A meta-analysis by Chang and coworkers (2017) [12] showed the irreversible inhibitor of MAO-B inhibitor rasagiline to have benefits both as a monotherapy and in combination with another intervention. The safety profile of rasagiline was similar to that of placebo in a systematic review of its use in PD patients [13]. Pramipexole, a nonergoline, D3-preferring dopamine agonist, is another treatment option for the management of motor symptoms associated with PD [14]. A recent systematic review showed that combined pramipexole and levodopa therapy was superior to levodopa monotherapy for the improvement of clinical symptoms in PD patients [15].
Prior systematic reviews evaluating the efficacy and safety of either rasagiline or pramipexole have evaluated patient populations at all stages of the disease. The goal of this study was to focus on the safety and efficacy of these drugs in early PD. Defining early PD in our review was based on the duration of PD in affected patients (five years or less) as well as the presence of mild to moderate symptoms based on the Hoehn and Yahr scale. The Hoehn and Yahr scale is commonly used in clinical studies to stage the level of functional disability and impairment seen in PD patients [16].
Results |